Rhabdomyosarcoma

Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements multimodality therapy resulted the improved overall survival for patients with low-risk intermediate-risk but not metastatic disease. We reviewed contrasted North American European practice patterns, though ultimately principles of staging, surgery, radiation therapy, chemotherapy are similar Children's Oncology Group International Society Paediatric treatment approaches. Efforts underway to investigate local control rates higher risk using dose escalation strategies, delayed primary excision select cases. The prognostic significance imaging-based response, proton novel biomarkers, targeted drugs will be determined upcoming clinical trials.